Press 
Releases 

ARTICLES

Mursla Bio named Best Emerging Biotech Company at the BioUK Awards 2026
Judged by a 33-member panel including leaders from Eli Lilly, Eisai and Ipsen

Mursla Bio publishes peer-reviewed validation of tissue-specific extracellular vesicle platform for liquid biopsy
Validates platform for new class of liquid biopsy: multiomic disease biology of living cells from a chosen tissue, starting with the liver
Mursla Bio accelerates US commercial deployment of EvoLiver through ABHI programme
Programme builds on existing US footprint and strengthens EvoLiver’s path to US clinical adoption
Mursla Bio collaborates with a leading global pharma company to advance biomarker-guided precision medicine in MASH
AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease
Mursla Bio introduces AI Precision Medicine Platform built on organ-specific EV isolation from blood
Organ-specific, AI-ready multi-omics platform validated for liver disease diagnostics and monitoring